Search Clinical Trials
| Sponsor Condition of Interest |
|---|
CONTAIN COVID-19: Convalescent Plasma to Limit COVID-19 Complications in Hospitalized Patients
NYU Langone Health
COVID-19
Coronavirus
Coronavirus Infection
This is a randomized, blinded phase 2 trial that will assess the efficacy and safety of
anti-SARS-CoV-2 convalescent plasma in hospitalized patients with acute respiratory
symptoms requiring oxygen supplementation. expand
This is a randomized, blinded phase 2 trial that will assess the efficacy and safety of anti-SARS-CoV-2 convalescent plasma in hospitalized patients with acute respiratory symptoms requiring oxygen supplementation. Type: Interventional Start Date: Apr 2020 |
|
Passive Immunity Trial for Our Nation to Treat COVID-19 in Hospitalized Adults
Vanderbilt University Medical Center
COVID-19
Coronavirus
SARS-CoV-2
The purpose of this study is to test the safety and efficacy of convalescent donor plasma
to treat COVID-19 in hospitalized adults in a randomized, placebo-controlled setting. The
effect of convalescent plasma will be compared to placebo on clinical outcomes, measured
using the COVID-19 7-point Ordinal... expand
The purpose of this study is to test the safety and efficacy of convalescent donor plasma to treat COVID-19 in hospitalized adults in a randomized, placebo-controlled setting. The effect of convalescent plasma will be compared to placebo on clinical outcomes, measured using the COVID-19 7-point Ordinal Clinical Progression Outcomes Scale at Day 15, among adults with COVID-19 requiring hospitalization. Type: Interventional Start Date: Apr 2020 |
Convalescent Plasma in Outpatients With COVID-19
Stanford University
Covid19
The overarching goal of this project is to confirm or refute the role of passive
immunization as a safe and efficacious therapy in preventing the progression from mild to
severe/critical COVID-19 illness and to understand the immunologic kinetics of
anti-SARS-CoV-2 antibodies after passive immunization.The... expand
The overarching goal of this project is to confirm or refute the role of passive immunization as a safe and efficacious therapy in preventing the progression from mild to severe/critical COVID-19 illness and to understand the immunologic kinetics of anti-SARS-CoV-2 antibodies after passive immunization.The primary objective is to determine the efficacy and safety of a single dose of convalescent plasma (CP) for preventing the progression from mild to severe COVID-19 illness. The secondary objective is to characterize the immunologic response to CP administration. This study will enroll adults presenting to the emergency department (ED) with mild, symptomatic, laboratory-confirmed COVID-19 illness, who are at high risk for progression to severe/critical illness, but who are clinically stable for outpatient management at randomization. Type: Interventional Start Date: Aug 2020 |
|
ACTIV-3: Therapeutics for Inpatients With COVID-19
National Institute of Allergy and Infectious Diseases (NIAID)
Covid19
This study looks at the safety and effectiveness of different drugs in treating COVID-19
in people who have been hospitalized with the infection. Participants in the study will
be treated with either a study drug plus current standard of care (SOC), or with placebo
plus current SOC. expand
This study looks at the safety and effectiveness of different drugs in treating COVID-19 in people who have been hospitalized with the infection. Participants in the study will be treated with either a study drug plus current standard of care (SOC), or with placebo plus current SOC. Type: Interventional Start Date: Aug 2020 |
|
COVID-19 Positive Outpatient Thrombosis Prevention in Adults Aged 40-80
Frank C Sciurba
COVID-19
A multi-center adaptive randomized placebo-controlled platform trial evaluating the
efficacy and safety of anti-thrombotic strategies in COVID-19 adults not requiring
hospitalization at time of diagnosis expand
A multi-center adaptive randomized placebo-controlled platform trial evaluating the efficacy and safety of anti-thrombotic strategies in COVID-19 adults not requiring hospitalization at time of diagnosis Type: Interventional Start Date: Sep 2020 |